Navigation Links
Napo Presents at ISPOR Meeting in Toronto
Date:5/12/2008

SOUTH SAN FRANCISCO, Calif., May 12 /PRNewswire-FirstCall/ -- Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU), announces that it presented a poster in collaboration with QualityMetric, Inc. describing the development of a patient reported outcomes questionnaire focused on the Health-Related Quality of Life (HR-QoL) aspects of chronic diarrhea in persons living with HIV/AIDS at the 13th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting in Toronto, Ontario, May 3 through 7, 2008.

Using classic and modern psychometric methods, a single scale comprised of 9 survey questions covering two HR-QoL content areas was developed. The survey questions showed consistency across gender, race and education level, demonstrated a statistically significant greater negative impact on HR-QoL with more frequent and more severe diarrhea symptoms.

Cathy Olufs, President, AIDS Activist Treatment Coalition (ATAC) stated, "We are fortunate to currently have a wide choice of HIV medications and combinations. This makes understanding medication side effects and their impact on a patient's quality of life more important than ever. Controlling side effects such as diarrhea can help give patients access to the full armamentarium of anti-retroviral drugs. We are pleased to see Napo taking the initiative to develop this new instrument to measure health-related quality of life as affected by diarrhea."

For more information please contract:

Napo Pharmaceuticals, Inc.

Lisa Conte, Chief Executive Officer

1 + 650 616 1902

David Golman, Pharm.D., Senior Director, Clinical Operations

1+ 760 918 5718

About Napo Pharmaceuticals, Inc.

Napo Pharmaceuticals, Inc. focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners. Napo was founded in November 2001, and is based in California, USA with a subsidiary in Mumbai, India.

Napo's late-stage proprietary gastro-intestinal compound, crofelemer, is in various stages of clinical development for four distinct product indications, including a late-stage Phase 3 program:

CRO-HIV for AIDS diarrhea, Phase 3

CRO-IBS for diarrhea irritable bowel syndrome ("D-IBS"), Phase 2

CRO-ID for acute infectious diarrhea (including cholera), Phase 2

CRO-PED for pediatric diarrhea, Phase 1

The FDA has granted fast-track status to CRO-IBS and CRO-HIV.

Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a medicinal plant which can be sustainably harvested from several countries in South America. Napo also plans to develop an early clinical stage product, NP-500, for the treatment of insulin resistant diseases of Type II diabetes and metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo also has a plant library of approximately 2,300 medicinal plants from tropical regions, and Napo has entered two screening relationship associated with this collection.

Currently, products are based on the chemical and biological diversity derived from plants with medicinal properties, but future products may be in-licensed from other sources.

Napo has partnerships with Glenmark Pharmaceuticals Limited of India and AsiaPharm Group Ltd. of China.

For more information please visit http://www.napopharma.com.

About ISPOR

ISPOR promotes the science of pharmacoeconomics (health economics) and outcomes research (the scientific discipline that evaluates the effect of health care interventions on patient well-being including clinical outcomes, economic outcomes, and patient-reported outcomes) and facilitates the translation of this research into useful information for healthcare decision-makers to ensure that society allocates scarce health care resources wisely, fairly and efficiently.


'/>"/>
SOURCE Napo Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
(Date:12/8/2016)... Dec. 8, 2016 Australia Glaucoma Surgery ... GlobalData,s new report, "Australia Glaucoma Surgery Devices Market ... the Australia Glaucoma Surgery Devices market. The report ... (in units) and average prices (USD) within market ... also provides company shares and distribution shares data ...
(Date:12/8/2016)... 8, 2016 KEY FINDINGS The ... in 2017-2023. Various reasons for growth of the medical ... incidences of chronic diseases, high recovery cost of injuries ... Medical lifting sling refers to an assistive device ... These slings connect to the lift and hold the ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman ... law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at ... DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology Group ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software ... and employees that are both engaging and easy to use. Coming off the ... software company revealed today its plans to roll out new AI-powered self-service enhancements ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
(Date:12/8/2016)... Dallas, TX (PRWEB) , ... December 08, 2016 , ... ... to continue to be a convenient service for Texas, they are expanding their presence ... will involve a hiring spree that will bring new jobs to the Dallas and ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients ... With this in mind, SIGVARIS has created a new line of anti-embolism stockings ... rest and provide the benefits of graduated compression when transitioning from recovery to ...
Breaking Medicine News(10 mins):